Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

被引：83

作者：

Buti, Sebastiano ^{[1
]}

Bersanelli, Melissa ^{[1
,2
]}

Perrone, Fabiana ^{[1
]}

Tiseo, Marcello ^{[1
,2
]}

Tucci, Marco ^{[3
,4
]}

Adamo, Vincenzo ^{[5
,6
]}

Stucci, Luigia S. ^{[3
]}

Russo, Alessandro ^{[5
,6
]}

Tanda, Enrica T. ^{[7
]}

Spagnolo, Francesco ^{[7
]}

Rastelli, Francesca ^{[9
]}

Pergolesi, Federica ^{[8
]}

Santini, Daniele ^{[9
]}

Russano, Marco ^{[9
]}

Anesi, Cecilia ^{[9
]}

Giusti, Raffaele ^{[10
]}

Filetti, Marco ^{[10
]}

Marchetti, Paolo ^{[10
,11
,12
]}

Botticelli, Andrea ^{[11
,12
]}

Gelibter, Alain ^{[12
]}

Occhipinti, Mario Alberto ^{[13
]}

Ferrari, Marco ^{[13
]}

Vitale, Maria Giuseppa ^{[14
]}

Nicolardi, Linda ^{[15
]}

Chiari, Rita ^{[15
]}

Rijavec, Erika ^{[16
]}

Nigro, Olga ^{[17
]}

Tuzi, Alessandro ^{[17
]}

De Tursi, Michele ^{[18
]}

Di Marino, Pietro ^{[19
]}

Conforti, Fabio ^{[20
]}

Queirolo, Paola ^{[20
]}

Bracarda, Sergio ^{[21
]}

Macrini, Serena ^{[21
]}

Gori, Stefania ^{[22
]}

Zoratto, Federica ^{[23
]}

Veltri, Enzo ^{[23
]}

Di Cocco, Barbara ^{[23
]}

Mallardo, Domenico ^{[24
]}

Vitale, Maria Grazia ^{[24
]}

Santoni, Matteo ^{[25
]}

Patruno, Leonardo ^{[26
,27
]}

Porzio, Giampiero ^{[26
]}

Ficorella, Corrado ^{[26
,27
]}

Pinato, David J. ^{[28
]}

Ascierto, Paolo A. ^{[24
]}

Cortellini, Alessio ^{[26
,27
]}

机构：

[1] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[2] Univ Parma, Dept Med & Surg, Parma, Italy

[3] Univ Bari, Dept Biomed Sci & Human Oncol, Med Oncol Unit, Bari, Italy

[4] Tumori Inst IRCCS Giovanni Paolo II, Natl Canc Res Ctr, Bari, Italy

[5] Univ Messina, AO Papardo, Med Oncol, Messina, Italy

[6] Univ Messina, Dept Human Pathol, Messina, Italy

[7] IRCCS Osped Policlin San Martino, Genoa, Italy

[8] Fermo Area Vasta 4, Med Oncol, Fermo, Italy

[9] Campus Biomed Univ, Med Oncol, Rome, Italy

[10] St Andrea Hosp Rome, Med Oncol Unit, Rome, Italy

[11] Sapienza Univ Rome, Dept Clin & Mol Med, Rome, Italy

[12] Sapienza Univ Rome, Policlin Umberto I, Med Oncol B, Rome, Italy

[13] Azienda Osped Univ Pisana, Med Oncol, Pisa, Italy

[14] Univ Hosp Modena, Med Oncol, Modena, Italy

[15] UOC Oncol Padova Sud AULSS6 Euganea, Padua, Italy

[16] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy

[17] Osped Circolo & Fdn Macchi, ASST Sette Laghi, Med Oncol, Varese, Italy

[18] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy

[19] SS Annuniata Hosp, Clin Oncol Unit, Chieti, Italy

[20] European Inst Oncol IRCCS, Div Med Oncol Melanoma Sarcoma & Rare Tumors, IEO, Milan, Italy

[21] Azienda Osped S Maria, SC Med Oncol, Terni, Italy

[22] IRCCS Osped Sacro Cuore Don Calabria, Oncol Unit, Negrar, VR, Italy

[23] Santa Maria Goretti Hosp, Med Oncol, Latina, Italy

[24] Ist Nazl Tumori IRCCS Fdn G Pascale, Melanoma Canc Immunotherapy & Dev Therapeut Unit, Naples, Italy

[25] Macerata Hosp, Dept Oncol, Macerata, Italy

[26] St Salvatore Hosp, Med Oncol Unit, Laquila, Italy

[27] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[28] Imperial Coll London, Hammersmith Hosp, Fac Med, Dept Surg & Canc, London, England

来源：

EUROPEAN JOURNAL OF CANCER | 2021年 / 142卷

关键词：

Concomitant medications; Drugs; Immunotherapy; Corticosteroids; Proton-pump inhibitors; Antibiotics; Immune checkpoint inhibitors; Cancer patients; Score; Index; Prognostic; PROTON PUMP INHIBITORS; GUT MICROBIOME; ANTIBIOTICS; EFFICACY; IMPACT; PD-1;

D O I：

10.1016/j.ejca.2020.09.033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Concomitant medications are known to impact on clinical outcomes of patients treated with immune checkpoint inhibitors (ICIs). We aimed weighing the role of different concomitant baseline medications to create a drug-based prognostic score. Methods: We evaluated concomitant baseline medications at immunotherapy initiation for their impact on objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in a single-institution cohort of patients with advanced cancer treated with ICIs (training cohort, N = 217), and a drug-based prognostic score with the drugs resulting significantly impacting the OS was computed. Secondly, we externally validated the score in a large multicenter external cohort (n = 1012). Results: In the training cohort (n=217), the median age was 69 years (range: 32-89), and the primary tumours were nonesmall-cell lung cancer (70%), melanoma (14.7%), renal cell carcinoma (9.2%) and others (6%). Among baseline medications, corticosteroids (hazard ratio [HR] = 2.3; 95% confidence interval [ CI]: 1.60-3.30), systemic antibiotics (HR = 2.07; 95% CI: 1.31-3.25) and proton-pump inhibitors (PPIs) (HR = 1.57; 95% CI: 1.13-2.18) were significantly associated with OS. The prognostic score was calculated using these three drug classes, defining good, intermediate and poor prognosis patients. Within the training cohort, OS (p < 0.0001), PFS (p < 0.0001) and ORR (p = 0.0297) were significantly distinguished by the score stratification. The prognostic value of the score was also demonstrated in terms of OS (p < 0.0001), PFS (p < 0.0001) and ORR (p = 0.0006) within the external cohort. Conclusion: Cumulative exposure to corticosteroids, antibiotics and PPIs (three likely microbiota-modulating drugs) leads to progressively worse outcomes after ICI therapy. We propose a simple score that can help stratifying patients in routine practice and clinical trials of ICIs. (C) 2020 Elsevier Ltd. All rights reserved.

引用

页码：18 / 28

页数：11

共 41 条

[1] Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Afzal, Muhammad Zubair
Mercado, Rima R.
Shirai, Keisuke
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[2] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Arbour, Kathryn C.
Mezquita, Laura
Long, Niamh
Rizvi, Hira
Auclin, Edouard
Ni, Andy
Martinez-Bernal, Gala
Ferrara, Roberto
Lai, W. Victoria
Hendriks, Lizza E. L.
Sabari, Joshua K.
Caramella, Caroline
Plodkowski, Andrew J.
Halpenny, Darragh
Chaft, Jamie E.
Planchard, David
Riely, Gregory J.
Besse, Benjamin
Hellmann, Matthew D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2872 - +
[3] The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes
Bersanelli, Melissa
Santoni, Matteo
Ticinesi, Andrea
Buti, Sebastiano
[J]. TARGETED ONCOLOGY, 2019, 14 (03) : 247 - 252
[4] External validation is necessary in, prediction research: A clinical example
Bleeker, SE
Moll, HA
Steyerberg, EW
Donders, ART
Derksen-Lubsen, G
Grobbee, DE
Moons, KGM
[J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (09) : 826 - 832
[5] Carrassi A, 2019, ATLAS OF PERIODONTOLOGY AND IMPLANT THERAPY, VOLS I & II, P1
[6] Chalabi M, 2020, ANN ONCOL, V31, P525, DOI [10.1016/j.annoc.2020.01.006, 10.1016/j.annonc.2020.01.006]
[7] Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
Cortellini, Alessio
Tucci, Marco
Adamo, Vincenzo
Stucci, Luigia Stefania
Russo, Alessandro
Tanda, Enrica Teresa
Spagnolo, Francesco
Rastelli, Francesca
Bisonni, Renato
Santini, Daniele
Russano, Marco
Anesi, Cecilia
Giusti, Raffaele
Filetti, Marco
Marchetti, Paolo
Botticelli, Andrea
Gelibter, Alain
Occhipinti, Mario Alberto
Marconcini, Riccardo
Vitale, Maria Giuseppa
Nicolardi, Linda
Chiari, Rita
Bareggi, Claudia
Nigro, Olga
Tuzi, Alessandro
De Tursi, Michele
Petragnani, Nicola
Pala, Laura
Bracarda, Sergio
Macrini, Serena
Inno, Alessandro
Zoratto, Federica
Veltri, Enzo
Di Cocco, Barbara
Mallardo, Domenico
Vitale, Maria Grazia
Pinato, David James
Porzio, Giampiero
Ficorella, Corrado
Ascierto, Paolo Antonio
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[8] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
Cortellini, Alessio
Tiseo, Marcello
Banna, Giuseppe L.
Cappuzzo, Federico
Aerts, Joachim G. J., V
Barbieri, Fausto
Giusti, Raffaele
Bria, Emilio
Cortinovis, Diego
Grossi, Francesco
Migliorino, Maria R.
Galetta, Domenico
Passiglia, Francesco
Santini, Daniele
Berardi, Rossana
Morabito, Alessandro
Genova, Carlo
Mazzoni, Francesca
Di Noia, Vincenzo
Signorelli, Diego
Tuzi, Alessandro
Gelibter, Alain
Marchetti, Paolo
Macerelli, Marianna
Rastelli, Francesca
Chiari, Rita
Rocco, Danilo
Gori, Stefania
De Tursi, Michele
Mansueto, Giovanni
Zoratto, Federica
Santoni, Matteo
Tudini, Marianna
Rijavec, Erika
Filetti, Marco
Catino, Annamaria
Pizzutilo, Pamela
Sala, Luca
Citarella, Fabrizio
Marco, Russano
Torniai, Mariangela
Cantini, Luca
Targato, Giada
Sforza, Vincenzo
Nigro, Olga
Ferrara, Miriam G.
D'Argento, Ettore
Buti, Sebastiano
Bordi, Paola
Antonuzzo, Lorenzo
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (11) : 2209 - 2221
[9] A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Cortellini, Alessio
Bersanelli, Melissa
Buti, Sebastiano
Cannita, Katia
Santini, Daniele
Perrone, Fabiana
Giusti, Raffaele
Tiseo, Marcello
Michiara, Maria
Di Marino, Pietro
Tinari, Nicola
De Tursi, Michele
Zoratto, Federica
Veltri, Enzo
Marconcini, Riccardo
Malorgio, Francesco
Russano, Marco
Anesi, Cecilia
Zeppola, Tea
Filetti, Marco
Marchetti, Paolo
Botticelli, Andrea
Cappellini, Gian Carlo Antonini
De Galitiis, Federica
Vitale, Maria Giuseppa
Rastelli, Francesca
Pergolesi, Federica
Berardi, Rossana
Rinaldi, Silvia
Tudini, Marianna
Silva, Rosa Rita
Pireddu, Annagrazia
Atzori, Francesco
Chiari, Rita
Ricciuti, Biagio
De Giglio, Andrea
Iacono, Daniela
Gelibter, Alain
Occhipinti, Mario Alberto
Parisi, Alessandro
Porzio, Giampiero
Fargnoli, Maria Concetta
Ascierto, Paolo Antonio
Ficorella, Corrado
Natoli, Clara
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[10] Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
Derosa, L.
Hellmann, M. D.
Spaziano, M.
Halpenny, D.
Fidelle, M.
Rizvi, H.
Long, N.
Plodkowski, A. J.
Arbour, K. C.
Chaft, J. E.
Rouche, J. A.
Zitvogel, L.
Zalcman, G.
Albiges, L.
Escudier, B.
Routy, B.
[J]. ANNALS OF ONCOLOGY, 2018, 29 (06) : 1437 - 1444

← 1 2 3 4 5 →